Abstract:The nuclear enzyme topoisomerase I (topo I) has been recently recognized as the target for the anticancer drug camptothecin (CPT) and its derivatives. Two of the agents that target this enzyme--topotecan (TPT) and CPT-11--appear to be active against a broad range of human tumors. In the following presentation, we review 1) the role of topo I in normal cells, 2) the chemistry and proposed mechanism of action of CPT and its analogues, 3) the results of preclinical and clinical testing of TPT and CPT-11, and 4) mechanisms of resistance to these agents. In normal cells, topo I is thought to be involved in gene transcription and DNA replication. During the course of its normal catalytic cycle, topo I transiently forms a covalent bond with DNA. CPT and its derivatives slow the religation step of the enzyme and stabilize the covalent adduct between topo I and DNA. In S-phase cells, advancing replication forks convert these topo I-DNA adducts into double-strand breaks that appear to be responsible for the cytotoxicity of these agents. Preclinical studies demonstrate antineoplastic activity for TPT and CPT-11 in a variety of tumor models. Phase I studies have identified neutropenia as the dose-limiting toxicity for both drugs. Gastrointestinal effects might also be dose-limiting for CPT-11 administered on some schedules. CPT-11 has shown antitumor activity in phase II trials for patients with carcinomas of lung, cervix, ovary, colon, and rectum and for patients with non-Hodgkin's lymphoma. Phase II studies of TPT are in progress. Resistance to the cytotoxic effects of these agents might result from decreased production of topo I or from production of a mutated form of topo I. In addition, decreased metabolic activation of CPT-11 (which is a pro-drug) and active efflux of TPT by P-glycoprotein-mediated transport might contribute to resistance. As agents with a novel mechanism of action, tolerable toxicity, and encouraging antitumor activity in early clinical trials, TPT and CPT-11 are undergoing further clinical development. If these agents can be successfully combined with other active chemotherapy agents, the topo I-directed agents offer the potential for significant advances in the treatment of patients with a variety of malignancies.

Perspectives on Biologically Active Camptothecin Derivatives

Review camptothecin: current perspectives.

Current status of CPT and its analogues in the treatment of malignancies

Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy

Research on Camptothecine (CPT) and its Derivative

The current status of camptothecin analogues as antitumor agents.

Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements

Two Novel Camptothecin Derivatives Inhibit Colorectal Cancer Proliferation Via Induction of Cell Cycle Arrest and Apoptosis in Vitro and in Vivo

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Drug combinations of camptothecin derivatives promote the antitumor properties

Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise

Design and Synthesis of Novel 7-[(N-substituted-thioureidopiperazinyl)-methyl]-camptothecin Derivatives As Potential Cytotoxic Agents.

Recent Progress on C‐4‐Modified Podophyllotoxin Analogs As Potent Antitumor Agents

Design and One-Pot Synthesis of New 7-Acyl Camptothecin Derivatives As Potent Cytotoxic Agents

Design, Synthesis, and Cytotoxic Activity of Novel 7-Substituted Camptothecin Derivatives Incorporating Piperazinyl-Sulfonylamidine Moieties.

Synthesis and Antitumor Activity of Novel 10-Substituted Camptothecin Analogues.

Possible Clues for Camptothecin Biosynthesis from the Metabolites in Camptothecin-Producing Plants

Camptothecin-based prodrug nanomedicines for cancer therapy

Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.

Topoisomerase I-mediated antiproliferative activity of 10-substituted and 12-substituted homocamptothecins

New Homocamptothecins: Synthesis, Antitumor Activity, and Molecular Modeling.